GMAB: Major phase III data for three assets expected next quarter, targeting broad first-line markets
Three major phase III assets are set for key data readouts next quarter, with epcoritamab, petosemtamab, and Rina-S targeting significant first-line and expansion opportunities. Epcoritamab's label updates and new indications are driving strong community uptake, while petosemtamab and Rina-S are po…